Montreal, Quebec – (June 2, 2025) – Defense Therapeutics Inc., a biotech firm specializing in advanced endosomal escape technologies, is planting its flag in the heart of the U.S. biotech boom. The company has announced the opening of its first U.S. laboratory in the Boston-Cambridge area, a strategic move designed to bolster its research and development efforts within one of the world’s leading biotech hubs.
This expansion marks a significant step for Defense Therapeutics, giving it a physical presence stateside and positioning it within a dynamic ecosystem of innovation. The new lab, located at Cambridge Scientific Labs in Watertown, will focus on the development and optimization of Defense Therapeutics’ proprietary Accum® technology, which is used in antibody-drug conjugates (“ADCs”), a rapidly growing field in cancer treatment. The location offers access to top-tier scientific resources and opportunities for collaboration, crucial components for driving innovation in the competitive biotech landscape. The Watertown facility is considered a short-term base, with Defense Therapeutics already assessing options for a more permanent long-term facility in the area.
“Establishing a U.S. laboratory is a major milestone for Defense Therapeutics,” said Sebastien Plouffe, CEO of Defense Therapeutics. “It cements our place at the center of the global biotech community and strengthens our commitment to advancing the Accum® platform for next-generation ADCs. We’re eager to deepen our footprint in the region and build a long-term presence in this vibrant market.”
About Defense Therapeutics:
Defense Therapeutics is a publicly-traded clinical-stage biotechnology company focused on developing the next generation of radio-immuno-conjugate and ADC products. The company’s core technology is its ACCUM® platform, designed to deliver radio-immuno-conjugates and ADCs directly to target cells without degradation. The promise is to increase the efficacy and potency of treatments, offering a potentially powerful weapon in the fight against cancer.
Cautionary Statement Regarding “Forward-Looking” Information
This release contains “forward-looking statements.” These statements, excluding historical facts, address expected events or developments. Forward-looking statements use words like “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” and similar expressions, or state that events or conditions “will,” “would,” “may,” “could,” or “should” occur. While the Company believes these statements are based on reasonable assumptions, actual results may differ. Factors affecting results include regulatory actions, market prices, capital availability, and economic conditions. Investors should be aware that future performance isn’t guaranteed and that actual results may vary. Forward-looking statements are based on current management beliefs, estimates, and opinions. The Company isn’t obligated to update these statements if management’s views or other factors change.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1519.html
